Now you can rely on the same proven technology platform throughout mouse and human stages of your T cell research.
for Mouse Research:
for Human in vitro Research:
for Clinical Research:
Dynabeads® Mouse T-Activator CD3/CD28Dynabeads® Human T-Expander CD3/CD28Dynabeads® CD3/CD28 CTS™

  • No need for feeder cells or Antigen Presenting Cells (APCs)
  • Isolate, activate and expand your T cells ex vivo with just one product
  • Obtain a 100-1000 fold expansion of T cells within 9-14 days
  • Obtain T cells with properties comparable to in vivo activated T cells
Dynabeads® CD3/CD28 CTS™ (formerly known as Xcyte™ Dynabeads® and Dynabeads® ClinExVivo™ CD3/CD28) is developed to optimize ex vivo T cell expansion in translational research while preserving T cell viability and optimal immune function.

These ready-to-use Dynabeads® are coated with antibodies directed against the TCR/CD3 and co-stimulatory CD28 receptors that are required for optimal T cell expansion.

The Dynabeads® ex vivo T cell expansion platform mimics in vivo activation and expansion

Scale up your research with the DynaMag™ CTS™ magnet

The DynaMag™ CTS™ magnet is developed for optimal performance with the Dynabeads® CD3/CD28 CTS™ technology, and allows you to work with large sample sizes (up to 10 L)

Legal and Regulatory

CD3/CD28In USA, Dynabeads® CD3/CD28 CTS™ are available for clinical use only under an approved IND application. A Device Master File is held at the US Food and Drug Administration for cross-referencing in Investigational New Drug (IND) applications.

References

  1. Thompson et al. A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2003, 9, 3562.
  2. Vij et al. A phase I/II study of Xcellerated T Cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2003, 102, Abstract 139.
  3. Kipps et al. A phase I/II trial of Xcellerated T Cells in patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2003, 102, Abstract 370.Thompson JA, et al. (2003). A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res. Sep 1;9(10 Pt 1):3562-70.
  4. Bartlett et al. A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2004, 104, Abstract 4640.
  5. Siegel et al. A phase I/II study of Xcellerated T Cells after autologous peripheral blood stem cell transplantation in patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2004, 104, Abstract 925.
  6. Castro et al. A phase I/II trial of Xcellerated T Cells in patients with Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 2004, 104, Abstract 2508.
  7. Berenson et al. A randomized phase II study of Xcellerated T Cells with or without prior Fludarabine therapy in patients with relapsed or refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2004, 104, Abstract 2410.
  8. Glode et al. A phase I/II trial of CD3/CD28 activated T cells (Xcellerated T Cells) in patients with hormone refractory prostate cancer. J Clin Oncol (ASCO Annual Meeting Proceedings) 2004, 22, Abstract 2549.
  9. Wierda et al. A phase I/II trial of CD3/CD28 activated T cells in patients with Chronic Lymphocytic Leukemia (CLL). J Clin Oncol (ASCO Annual Meeting Proceedings) 2004, 22, Abstract 2566.
  10. Kipps et al. A phase I/II study of Xcellerated T Cells in patients with Chronic Lymphocytic Leukemia. J Clin Oncol (ASCO Annual Meeting Proceedings) 2005, 23, Abstract 2511.